@prefix dct: .
@prefix obo: .
@prefix orcid: .
@prefix this: .
@prefix sub: .
@prefix rdfs: .
@prefix xsd: .
@prefix sio: .
@prefix lld: .
@prefix miriam-gene: .
@prefix miriam-pubmed: .
@prefix wi: .
@prefix prov: .
@prefix pav: .
@prefix prv: .
@prefix np: .
@prefix dgn-gda: .
@prefix dgn-void: .
sub:head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:publicationInfo;
a np:Nanopublication .
}
sub:assertion {
dgn-gda:DGNb559ef4ef688ab4d4162c52efe4a3a69 sio:SIO_000628 miriam-gene:238, lld:C0007131;
a sio:SIO_001122 .
}
sub:provenance {
sub:assertion dct:description "[This review will describe the biology and significance of ALK rearrangements in NSCLC, ALK inhibition by crizotinib and mechanisms of resistance, as well as the preclinical and clinical evidence for the novel ALK inhibitor alectinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en;
wi:evidence dgn-void:source_evidence_literature;
sio:SIO_000772 miriam-pubmed:25876560;
prov:wasDerivedFrom dgn-void:BEFREE;
prov:wasGeneratedBy obo:ECO_0000203 .
dgn-void:BEFREE pav:importedOn "2017-02-19"^^xsd:date .
dgn-void:source_evidence_literature a obo:ECO_0000212;
rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en;
rdfs:label "DisGeNET evidence - LITERATURE"@en .
}
sub:publicationInfo {
this: dct:created "2017-10-17T13:10:26+02:00"^^xsd:dateTime;
dct:rights ;
dct:rightsHolder dgn-void:IBIGroup;
dct:subject sio:SIO_000983;
prv:usedData dgn-void:disgenetv3.0rdf;
pav:authoredBy orcid:0000-0001-5999-6269, orcid:0000-0002-7534-7661, orcid:0000-0002-9383-528X,
orcid:0000-0003-0169-8159, orcid:0000-0003-1244-7654;
pav:createdBy orcid:0000-0003-0169-8159;
pav:version "v5.0.0.0" .
dgn-void:disgenetv3.0rdf pav:version "v5.0.0" .
}